Literature DB >> 32504568

Weighing considerations with newer antiretrovirals.

W D Francois Venter1, Andrew Hill2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32504568     DOI： 10.1016/S2352-3018(20)30115-6

Source DB:  PubMed          Journal:  Lancet HIV        ISSN： 2352-3018            Impact factor:   12.767


× No keyword cloud information.
  1 in total

1.  Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).

Authors:  D Podzamczer; R Micán; J Tiraboschi; J Portilla; P Domingo; J M Llibre; E Ribera; M J Vivancos; L Morano; M Masiá; C Gómez; F Fanjul; A Payeras; A Inciarte; V Estrada; A Rivero; Á Castro; E Bernal; D Vinuesa; H Knobel; J Troya; J Macías; M Montero; J Sanz; A Navarro-Alcaraz; A Caicedo; G Fernández; E Martínez; S Moreno
Journal:  Open Forum Infect Dis       Date:  2021-11-25       Impact factor: 3.835
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.